Urinary tract infections in patients with neurogenic bladder.
Bactéries multi-résistantes
Infections urinaires
Multidrug-resistant bacteria
Neurogenic bladder
Prevention
Prévention
Urinary tract infections
Vessie neurologique
Journal
Medecine et maladies infectieuses
ISSN: 1769-6690
Titre abrégé: Med Mal Infect
Pays: France
ID NLM: 0311416
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
02
05
2018
revised:
04
09
2018
accepted:
21
02
2019
pubmed:
20
3
2019
medline:
23
4
2020
entrez:
20
3
2019
Statut:
ppublish
Résumé
Urinary tract infections (UTIs) in patients with neurogenic bladder are a major public health issue due to their high incidence and major consequences. Despite their frequency and potential severity, their physiopathology and management are poorly known. We provide a narrative literature review on the epidemiology, physiopathology, diagnostic criteria, microbiology, antimicrobial management, and prevention. UTIs among patients with neurogenic bladder are associated with high morbidity and healthcare utilization. Risk factors for UTI among this population are: indwelling catheter, urinary stasis, high bladder pressure, and bladder stones. Their diagnosis is a major challenge as clinical signs are often non-specific and rare. A urinary sample should be analyzed in appropriate conditions before any antibiotic prescription. According to most guidelines, a bacterial threshold≥103CFU/ml associated with symptoms is acceptable to define UTI in patients with neurogenic bladder. The management of acute symptomatic UTI is not evidence-based. A management with a single agent and a short antibiotic treatment of 10 days or less seems effective. Antibiotic selection should be based on the patient's resistance patterns. Asymptomatic bacteriuria should not be treated to avoid the emergence of bacterial resistance. Regarding preventive measures, use of clean intermittent catheterization, intravesical botulinum toxin injection, and prevention using antibiotic cycling are effective. Bacterial interference is promising but randomized controlled trials are needed. Large ongoing cohorts and randomized controlled trials should soon provide more evidence-based data.
Identifiants
pubmed: 30885540
pii: S0399-077X(18)30613-9
doi: 10.1016/j.medmal.2019.02.006
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-504Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.